Phase II clinical trial of ShigETEC
Latest Information Update: 17 Sep 2020
At a glance
- Drugs Escherichia coli/Shigella oral vaccine-Eveliqur Biotechnologies (Primary)
- Indications Traveller's diarrhoea
- Focus Therapeutic Use
- 14 Sep 2020 New trial record
- 09 Sep 2020 According to an Eveliqure Biotechnologies GmbH media release, the company received the award of a US government contract from the National Institute of Allergy and Infectious Diseases (NIAID), contract #75N93020C00048 with the intent to fund the development of its vaccine candidate, ShigETEC, through Phase 2 clinical testing.